RMD ResMed Inc.

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) --

When:          May 17–22, 2024

Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101

                       Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101

Research:     26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights:

  • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV)

    in Opioid Users – a European Registry
    • Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-B
    • Presented by Jean-Louis Pepin, MD, Grenoble Alpes University, France
  • An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States into 2050
    • Monday, May 20, 9:15 a.m. - 4:15 p.m., SDCC Area C Hall A-B2
    • Presented by Elroy Boers, PhD, ResMed Science Center
  • All-Cause Mortality in Obstructive Sleep Apnea
    • Monday, May 20, 2:15 p.m. - 4:15 p.m., SDCC 32A-B
    • Presented by Atul Malhotra, MD, University of California, San Diego
  • Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare Database
    • Monday, May 20, 2:15 p.m. - 4:15 p.m., SDCC 32A-B
    • Presented by Holger Woehrle, MD, Ulm Lung Centre, Germany
  • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation – Outcomes in Patients with Treatment-Emergent or Persistent Central Sleep Apnea
    • Tuesday, May 21, 2:15 p.m. - 4:15 p.m., Marriott Marquis Pacific Ballroom 15-17
    • Presented by Michael Arzt, MD, Universitätsklinikum Regensburg, Germany

Innovation Hub:     Healthcare of Today, Looking Towards Tomorrow: Digital Innovations and Patient Centricity

  • Monday, May 20, 1:15 - 1:35 p.m., SDCC Innovation Hub 4
  • Presented by Monica Mallampalli, Chief Executive Officer at Alliance of Sleep Apnea Partners, and Carlos Nunez, ResMed Chief Medical Officer

Booth #1442:            Featuring ResMed’s latest innovations in respiratory care:

  • AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
  • AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask

Complete list of ResMed sponsored studies to be presented at ATS 2024:

Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) in opioid users – a European registrySunday, May 19, 2024

9:15 AM -11:15 AM
8-year Trends in Obesity, Type 2 Diabetes, and Glucagon-like Peptide-1 (GLP-1) Use in Patients With Obstructive Sleep ApneaSunday May 19, 2024

9:15 AM - 11:15 AM
Impact of CPAP Termination on Permanent Work Disability in Obstructive Sleep Apnea: A French Nationwide Alaska Database AnalysisSunday May 19, 2024

9:15 AM - 4:15 PM
Tailoring Social Support to Improve PAP Therapy Usage in Obstructive Sleep ApneaSunday May 19, 2024

9:15 AM - 4:15 PM
Examining Alignment of Patient Medication-taking Behaviors With Inhaler Usage Recommendations in Chronic Obstructive Pulmonary Disease and AsthmaSunday May 19, 2024

9:15 AM - 4:15 PM
Using Natural Language Processing for Qualitative Research: Insights From a Real-world AnalysisSunday May 19, 2024

9:15 AM - 4:15 PM
A Qualitative Analysis of Perceptions and Awareness of Air Pollution and Its Health Effects in Asthma Among Asthma-care Professionals Across Southern CaliforniaMonday May 20, 2024

9:15 AM - 4:15 PM
An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States Into 2050Monday May 20, 2024

9:15 AM - 4:15 PM
All-cause Mortality in Obstructive Sleep Apnea: Systematic Literature Review Including Randomised Trials and Confounding Adjusted Non-randomised Controlled Studies and Meta-analysis of Positive Airway Pressure TreatmentMonday May 20, 2024

2:15 PM - 4:15 PM
Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare DatabaseMonday May 20, 2024

2:15 PM - 4:15 PM
Hypoxic Burden but Not AHI Predicts Risk of Cardiovascular Events: A Secondary Analysis of the RICCADSA Clinical TrialMonday May 20, 2024

2:15 PM - 4:15 PM
A Digital Quality Improvement Program Delivered By Clinical Pharmacists Can Reduce Acute Care Visits In COPDMonday May 20, 2024

2:15 PM - 4:15 PM
Hands-on Simulation Training With Home Ventilators Improves PCCM Fellow Understanding of Nocturnal NIV in Chronic HypercapniaMonday May 20, 2024

2:15 PM - 4:15 PM
The Economic and Health Burden of COPD in North America Through 2050: A Scenario Analysis Based on Two Large Data SourcesTuesday May 21, 2024

9:15 AM - 11:15 AM
Impact of long-term domiciliary noninvasive ventilation (NIV) on severe exacerbations and survival in Patients with Chronic Obstructive Pulmonary Disease (COPD): a nationwide cohort study using multistate modelsTuesday May 21, 2024

9:15 AM - 11:15 AM
Nocturnal Hypoxemic Burden and Micro- and Macrovascular Disease in Patients With Type 2 DiabetesTuesday May 21, 2024

9:15 AM - 11:15 AM
Risk Factors for Severe Exacerbation Occurrence Among Patients With COPD-OSA Overlap Syndrome Using Bilevel Positive Airway Pressure TherapyTuesday May 21, 2024

9:15 AM - 4:15 PM
Adherence to Glucagon-like Peptide-1 Receptor Agonists (GLP-1s) in Obstructive Sleep Apnea Patients With and Without Type 2 DiabetesTuesday May 21, 2024

2:15 PM - 4:15 PM
Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) – outcomes in patients with treatment-emergent or persistent central sleep apnea (TE-CSA) in a European registryTuesday, May 21, 2024

2:15 PM – 4:15 PM
A Scenario-based Modeling Study to Project the Future Burden of COPD in the United States Accounting for the Effects of E-cigarettesTuesday May 21, 2024

2:15 PM - 4:15 PM
The Impact Of Weight Change On Positive Airway Pressure Use In Patients With Obstructive Sleep Apnea And ObesityTuesday May 21, 2024

2:15 PM - 4:15 PM
Real World GLP-1 Adherence in Patients with Treated Obstructive Sleep ApneaTuesday May 21, 2024

2:15 PM - 4:15 PM
Less REM Sleep Predicts Mortality in Adults With Coronary Artery Disease and Obstructive Sleep Apnea: The RICCADSA TrialTuesday May 21, 2024

2:15 PM - 4:15 PM
Gender Specific Differences in a National Sample of Individuals with Comorbid Insomnia, Obstructive Sleep Apnea (OSA), and DepressionWednesday May 22, 2024

8:15 AM - 10:15 AM
Use of Weight Management Regimens Among Positive Airway Pressure-Treated Patients With Obstructive Sleep Apnea and ObesityWednesday May 22, 2024

11:00 AM - 1:00 PM
A Mixed-methods Exploration of Patient Perspectives on Pap Therapy Initiation: Implications for Improved Outreach and EducationWednesday May 22, 2024

11:00 AM - 1:00 PM





Media questions/requests:        
Peter Duckler, +1 (773) 343-3069,  
Rowena Kelley, +1 (858) 289-7272,  
EN
16/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for P...

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and th...

 PRESS RELEASE

Developed in Collaboration with Leading Scientists, New ResMed-Support...

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA)Prevalence of OSA in the United States expected to increase 26.7% in men and women aged 30 –70Real-world trends of glucagon-like peptide-1 (GLP-1) receptor agonist and PAP therapy use show patient...

 PRESS RELEASE

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence o...

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When:          May 17–22, 2024Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101                       Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research:     26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights: Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilat...

 PRESS RELEASE

ResMed Announces Participation in the RBCCM Global Healthcare Conferen...

ResMed Announces Participation in the RBCCM Global Healthcare Conference SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Dr. Carlos Nunez, Chief Medical Officer, and Amy Wakeham, Chief Investor Relations Officer, will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, beginning at approximately 4:05 p.m. (Eastern Daylight Time) at the InterContinental New York Barclay, in New York, NY. More information about this event, including access to the live, audio-only webcast, may be accessed by visitin...

 PRESS RELEASE

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 202...

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024 Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024. Third Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 7% to $1.2 billion; up 7% on a constant currency ba...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch